Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy

"We are very excited about Nefecon's approval in China. There is clearly a very significant need amongst IgAN patients in China to have access to an approved medication specifically designed to target the origin of the disease and which provides hope of disease modification," says CEO Renée Aguiar-Lucander. "We are very excited about Nefecon's approval inChina. There is clearly a very significant need amongst IgAN patients inChinato have access to an approved medication specifically...

"We are very excited about Nefecon's approval in China. There is clearly a very significant need amongst IgAN patients in China to have access to an approved medication specifically designed to target the origin of the disease and which provides hope of disease modification," says CEO Renée Aguiar-Lucander.

Results from the Chinese subpopulation analysis of the Phase 3 NefIgArd trial, presented at the American Society of Nephrology (ASN) Kidney Week 2023, provided evidence that the treatment effect of Nefecon in the Chinese cohort was greater than in the global data set with regards to kidney function, proteinuria and microhematuria. In the Chinese cohort, the mean absolute change from baseline in eGFR at 24 months showed an approximately 66% reduction in loss of this measure of kidney function with Nefecon compared with a 50% reduction in loss of eGFR in the global data set.

This approval triggers a milestone payment of five million USD to Calliditas, which will be included as revenue in the fourth quarter.

CONTACT:

For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information was sent for publication, through the agency of the contact person set out above, on November 24, 2023 at 08:45 a.m. CET.

The following files are available for download:

 

 

View original content:https://www.prnewswire.co.uk/news-releases/calliditas-partner-everest-medicines-announces-china-nmpas-approval-of-nefecon-for-the-treatment-of-primary-iga-nephropathy-301997026.html